Inventiva faces resistance but has solid fundamentalsOn an uptrend near the 210-day MA (30 weeks) (Wall around €5) . Key takeaways:
- Clinical advances on lanifibranor
- Financing and partnerships (including rumors from US pharmaceutical giants)
- Cash flow increasing until mid-2026.
Analysts' speculative price target around €8. Everything will depe
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.46 EUR
−192.48 M EUR
9.61 M EUR
136.98 M
About Inventiva SA
Sector
Industry
CEO
Frédéric Cren
Website
Headquarters
Daix
Founded
2011
ISIN
US46124U1079
FIGI
BBG00VYK2907
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Related stocks
Possibility of strong rise, but beware of speculatorsThis increase of more than 30% of November 1 is not obtained as a result of news concerning Inventiva, caution, therefore, following the speculators who can in the short term vary the action.
In the long run, I think it's a big possibility if the products work and the tests succeed one after the ot
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.